Tuesday, May 18, 2010

Recovery Rides In On The Rails

This piece was posted early this morning on Investopedia. 
http://stocks.investopedia.com/stock-analysis/2010/Recovery-Rides-In-On-The-Rails-UNP-CP-CNI-NSC-CSX-BTU0518.aspx 

I strongly recommend Rail Times Indicators; it is an excellent source of information on what's going on with North American railroads.

If you really want to know what is going on in the economy, you cannot just look at the flashy headline economic data that comes out every month. You need to know what is happening at the "street level", and that is why I am a fan of following railroad traffic data.

According to data produced by the American Association of Railroads (in its monthly Rail Time Indicators report), U.S. carloads jumped almost 16% from the year-ago level and hit their highest number since November 2008. Likewise, Canada was quite strong - carloads jumped almost 27% annually and ended up at a level not seen since October 2008.

The rest of the article can be read at Investopedia: 
   http://stocks.investopedia.com/stock-analysis/2010/Recovery-Rides-In-On-The-Rails-UNP-CP-CNI-NSC-CSX-BTU0518.aspx

Monday, May 17, 2010

Does A123 Have The Juice?

Investing in potentially game-changing technology comes at a cost. By the time you know the winners from the losers, a large percentage of the gains are already in the hands of those investors who stepped up when there were more doubts than answers. On the other hand, investing in these companies is a virtual guarantee of volatility and runs a serious risk of capital loss. 

All that said, battery maker A123 (Nasdaq:AONE) in one of those plays that may be worth the risk. Although the stock has been weak lately and first-quarter earnings will not help matters, these are still early days for the company, the technology, and the industry as a whole.  

For the full text of the article: http://stocks.investopedia.com/stock-analysis/2010/Does-A123-Have-The-Juice-AONE-BLDP-SWK-JCI-HEV0517.aspx

Thursday, May 13, 2010

A Few Fruits From This Week's Research

When you're a stock junkie (to say nothing of a financial writer), you're pretty much always doing stock research. Sometimes you go a while before finding good ideas, and then sometimes you find them in bunches.

This week turned up a few interesting tidbits, as I was looking mostly at the chemicals sector.

Goodyear (GT) - Analysts seem to like this one, and it was up more than 10% in the past week. But a tire company? Really? Sure, the EV/EBITDA ratio isn't bad, but this company's historical ability to produce real returns (ROIC) isn't very good.

Aceto (ACET) - I like the idea of a company that makes the chemical underpinnings of pharmaceuticals, particularly generics. By and large, these guys don't mess with the legal patent wrangling like a TEVA. The EV/EBITDA is on the high side, but this one looks interesting.

Calgon Carbon (CCC) - Wow. Great business and decent returns on capital, but a pretty poor long-term record of growth and doesn't look at all cheap to me (though the analysts seem to like it well enough).

Hexcel (HXL) - Nice story (carbon fiber for Boeing and Airbus), but I can't even get close to making this one work on a valuation basis.

Lubrizol (LZ) - Am I the only one who didn't know this company was producing double-digit ROICs, good growth, and a strong free cash flow yield? Unfortunately, as much as the company looks like a winner, the stock seems to be there already.

Metabolix (MBLX) - You either win big or lose big. It's a nice idea, making plastics out of corn, switchgrass, and the like, but valuation is an exercise in faith. Treat it like a biotech. I probably should go back and double-check the IP here, because that will be the real deciding factor.

Methanex (MEOH) - I was shocked at how cheap this one looks when I value it by a forward EBITDA basis. It's been a volatile commodity business in the past, but they have a lot of unused capacity (good for margins if volumes go up) and China seems poised to use a lot more methanol.

Sigma Aldrich (SIAL) - Great company. No bargain in the stock, though.

Huntsman (HUN) - Hmmm. This one could be interesting. It's a diversified chemicals business, but a little less commoditized than your average commodity business. This one could be worth a closer look.

Landec
(LNDC) - This was a popular "little known" growth stock a few years ago. It was supposed to be a company that "looked like a commodity business, but really wasn't". Guess what? It was. At least enough to knock the wind out of its sales. I'm intrigued, though, and if my numbers are right this could be a cheap one.

And so ends the gleanings from this week's research. There were a lot more names I looked at, but I feel like 10 at a time is about all anybody wants to read about.

Happy hunting!

An Increasingly Small World For Disney

Sometimes, conventional wisdom is not so wise. Take the case of media giant Disney (NYSE:DIS) - the conventional wisdom is that the popularity and ubiquity of its brands (and its eternal appeal to kids) insulates it from economic conditions. That so-called wisdom bypasses the reality that it takes money to go to theme parks, advertising on networks trails off in recessions and movie production requires large upfront investments for uncertain returns. 

Diversification Shows its AdvantagesThat said, Disney's diversified asset base has helped the company weather the downturn in relatively good order, and this quarter was another example. Revenue rose about 6% overall as strength in the cable and film business offset pretty iffy results in broadcast TV and theme parks. Margins likewise have stayed strong, even as the company lays out significant money for programming rights for ESPN. One note of caution on the margins, though. Successful movies like Alice in Wonderland can certainly boost profitability, but seemingly every studio has a dry spell from time to time and they are inherently impossible to predict (few studio execs would green-light a movie they know is doomed to fail).  

http://stocks.investopedia.com/stock-analysis/2010/An-Increasingly-Small-World-for-Disney-DIS-CMCSA-GE-CBS-NWS-FUN-VIVDY0513.aspx

Will Adaptive Design Change the BioPharma World?

I wrote the following for Investopedia, and it was published today. 
I'm actually pretty interested in seeing what, if any, reaction I get to this. I really do believe this is one of the bigger ideas that could emerge in biopharma over the next few years, but it is an idea that you scarcely hear about outside of occasional panels and forums at industry conferences and meetings. 

I hope you find it interesting. 

Every so often a good idea comes out way ahead of its time. Fuel cells actually predate the gasoline engine, the Apple (Nasdaq:AAPL) Newton is the almost-forgotten iPad/iPhone predecessor, and Nikola Tesla sketched out plans for concepts like wireless energy transfer and airplanes that could take off vertically in the 1920s.  

Adaptive clinical trial design may ultimately belong on this list as well. Although the idea of changing pharmaceutical drug trials in response to data generated within the trial has been around for at least 10 years, the idea may finally be on the cusp of being realized. Should this concept become more commonplace, it could be a major step forward for biotechnology and pharmaceutical companies.

Read the full column at: 
http://stocks.investopedia.com/stock-analysis/2010/Will-Adaptive-Design-Change-The-BioPharma-World-AMGN-GILD-ITMN-EXEL-LLY-PFE-PRXL0513.aspx  

Wednesday, May 12, 2010

A Private Deal For Sequenom

Interesting little deal today in the diagnostics space.  

Sequenom (SQNM) announced a private placement of 12.4M shares at a price of $4.15/sh ($51.6M total). The company definitely needs the cash to continue its R&D program, and the size of this deal should calm the funding fears for a while.Still, I can't help but notice that the investors in this deal demanded a pretty substantial discount to the prevailing stock price - nearly a 25% haircut to today's opening price.

To me, that seems like a pretty fair discount given the concerns and controversy around this company. There are plenty of places where you can read about the details, but the gist of it is that a major scandal hit the company last year; costing most of the sr. mgmt their jobs, costing the company several lawsuits, and throwing into question whether or not the company's lead test even works. On top of that, I'm still under the impression that the owner of the underlying technology (who had extended SQNM a license) wants out of that agreement.

So, in other words, this is a $340M market cap company trading basically on the hope that their test for Down's Syndrome works (but where the past data is all but useless because of the possibility of deliberate bias in prior studies) and that they still have the rights to develop and market it. Given all that, then, a 25% discount is not an unreasonable margin of safety.

On a more positive note, the company gave pretty clear guidance last week regarding the development timeline for this test, with test optimization expected to be over by the end of Q3'10, testing of samples conducted in the fourth quarter, and commercial launch by the end of 2011.Now, maybe I'm reading too much into this, but doesn't this sound a bit like "back to the drawing board?" If  they're having to go back to test optimization, that suggests to me that there were at least a few significant flaws in the old test. Whether that completely invalidates the old promise or not, I do not know. Unfortunately, I don't think anybody outside the company knows either, so it's basically an exercise of faith at this point.

I happen to think that the baseline technology the company is using is pretty sound, and I think there's some real market potential for this test. But with so many other options to chose from, and options that offer "clean" stories, I just don't see the need to take the risk here right now.

Good Luck, Peter

Saw an announcement after today's close that Peter Donato has resigned from his position as CFO at IRIS International. I had the pleasure of interacting with him a number of times while I covered his company as a sell-side analyst. Much as it pains me to praise any fan of Ohio State and the Detroit Redwings, I always enjoyed interacting with Peter, and IRIS is poorer for his departure.

I won't even begin to speculate as to why he is leaving the company and what it may, or may not, mean. People move on in business and it's just a fact of life. Still, it's another ripple through a company that seems to be pretty much cursed with them. Given what the company hopes to accomplish in the near term - filing for VELOCITY, securing FDA approval for ProsVue, launching those two products in the US, and rebuilding the company's reputation with the Street -- that is a pretty significant shake-up for the company.

I guess the "good news" here for an IRIS shareholder is that the value of the stock is pretty much based upon what the company *should* be able to do and not what it has been doing recently. Accordingly, assuming that the company recruits a qualified candidate, it shouldn't really impact the story over the long-term. Still, I would be nervous about what this management shake-up is going to do to the company's launch plans.

Again, best of luck Peter!

Has Europe Risen To The Challenge?

This is a bit out of date now, as it seems like the market has more or less digested the ECB rescue package and deemed it "good enough ... for now".

After seeing punishing increases in interest rates, declines in the euro and chaos in the equity markets in response to slow and unsteady action on Greece, the ministers of the European Union decided to try to get ahead of the next round of worry and launch a massive liquidity measure for its members. The announced package immediately sent the euro higher along with equities of all stripes, but especially those exposed to the financial chaos in Europe.

What HappenedEarly on Monday morning, the finance ministers of the EU announced an enormous liquidity package designed to restore faith in the euro and the solvency of its members. The three-part program is worth almost $1 trillion and it consists of 60 billion euros in loans, 440 billion euros in future loan guarantees and as much as 250 billion euros in funding from the IMF.
  
The full column can be read at: http://financialedge.investopedia.com/financial-edge/0510/Has-Europe-Risen-To-The-Challenge.aspx

Meaty Results From Zhongpin and Tyson

These are pretty fat days to be in the protein business. Corn and soy prices, the two primary feed ingredients, are about as low as they have been in a few years, while prices for hogs and cattle are quite high. That margin, which goes by the somewhat grizzly name of "crush spread", is music to the ears of major meat producers like Tyson Foods (NYSE:TSN), while China's Zhongpin (Nasdaq:HOGS) also continues to see a benefit from ongoing economic development in its home country. 

http://stocks.investopedia.com/stock-analysis/2010/Meaty-Results-From-Zhongpin-And-Tyson-TSN-HOGS-SFD-MCD-YUM-PEP-KFT0512.aspx

Penn Virginia Turning Coal Into Cash

Penn Virginia has been one of my favorite companies for a while, and it's a company that I have written about a lot over the years. Oddly enough, I've never actually pulled the trigger and owned it in my own portfolio. Maybe soon, though...

Say you want to invest a portion of your portfolio in coal, America's dominant energy source for electricity, but you also want to get a hefty stream of income from that investment. Unfortunately for dividend-seeking investors, the leading names in the coal industry like Peabody Energy (NYSE:BTU), Arch Coal (NYSE:ACI) and  Massey Energy Co. (NYSE:MEE) do not pay especially large dividends. What do you do?  

Well, you could try to buy a share in a coal mine lease, but that is quite frankly not an option for most regular people. You could also pursue a covered call writing strategy, but that may be a bit too much work for some investors. Or, you could also just buy the shares of a royalty partnership like Penn Virginia Resources (NYSE:PVR). 

http://stocks.investopedia.com/stock-analysis/2010/Penn-Virginia-Turning-Coal-Into-Cash-PVR-BTU-ACI-MEE-RRC-EOG-ARLP-NRP0512.aspx  

Tuesday, May 11, 2010

Earnings From a Couple of Gas Giants

There is an argument out there that closely analyzing the quarterly financial performance of energy companies is basically futile. The impact of energy prices is so significant, the thinking goes, that it renders the company-specific details basically meaningless. 

But if you look at long-term charts of the players in the energy space, you will see that the stocks of efficient and savvy producers outperform over time. So while a penny of earnings here or there is not going to dominate the discussion around Devon Energy (NYSE:DVN) or Ultra Petroleum (NYSE:UPL), investors would do well to dig in and appreciate what distinguishes the best operators. 


http://stocks.investopedia.com/stock-analysis/2010/Earnings-From-A-Couple-of-Gas-Giants-DVN-UPL-APA-SWN-CHK0511.aspx

Transocean Far From Sunk

There is no need to minimize just how serious the Deepwater Horizon oil spill in the Gulf of Mexico could ultimately be. Workers died in the accident, billions of dollars in damage are likely, a valuable rig is now scrap metal, and opponents of offshore drilling will make hay from this accident for years to come. 

All of that being said, the decline in market value of offshore driller Transocean (NYSE: RIG) seems to be exaggerating the ultimate impact to the company and its future prospects. With earnings out last week and a growing sense of the worst-case scenarios, the nervous hands may be all but gone from this story.  

http://stocks.investopedia.com/stock-analysis/2010/Transocean-Far-From-Sunk-RIG-BP-CAM-SII-PBR-FTI-CGV-HAL-APA-XOM0511.aspx

Monday, May 10, 2010

FDA Makes InterMune Sick (ITMN, GSK, AZN, GILD, VRTX, ACHN, VRUS)



I originally wrote this piece right after InterMune announced its FDA setback, but there was a bit of a logjam in the editing process. In any case, there are still some valuable points here. 

Failure is an inherent risk in the boom-and-bust world of biotech, and InterMune (Nasdaq: ITMN) shareholders saw that risk play out on Wednesday morning. The FDA effectively rejected the company's application for marketing approval of Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis. 

Clearly the damage has already been done, but what InterMune investors must decide now is whether there is enough promise in the drug and the company to hang on in the hopes of a rebound. 

For the rest of the article, please click on the following link:
http://stocks.investopedia.com/stock-analysis/2010/FDA-Makes-InterMune-Sick-ITMN-GSK-AZN-GILD-VRTX-ACHN-VRUS0510.aspx

Friday, May 7, 2010

Greece: The Worst-Case Scenario

This (http://financialedge.investopedia.com/financial-edge/0510/Greece-The-Worst-Case-Scenario.aspx) went up yesterday afternoon, so I apologize for the late posting.

While there has been a great deal of attention paid over the last few months to the nascent recovery in the United States, the ongoing Greek sovereign debt crisis in Europe is a reminder that there are often long-tail effects to recessions and global economic shake-ups. 


How Did This Happen?What has happened is the result of a long series of bad decisions. The establishment of the euro effectively gave Greece access to a huge amount of relatively cheap debt, but Greek officials did not put the proceeds of this debt to good use. Since the euro came into existence, Greece's ratio of debt to GDP has stayed above 100% and the country ran persistent deficits in excess of 10% of GDP. Ultimately, when investors (and, belatedly, the ratings agencies) realized that the emperor had no clothes, rates on Greek debt began to creep up, and matters culminated in the S&P downgrade of Greek debt to "junk" status on April 27 of 2010.

For the rest, please click on through to:  http://financialedge.investopedia.com/financial-edge/0510/Greece-The-Worst-Case-Scenario.aspx

Thursday, May 6, 2010

Ouch! Nasty Whiplash

This is why I try to keep the TV-watching to a minimum during the workday. In maybe 20 minutes I've seen the market plummet from down 5% to down more than 9% to now down about 4% (and climbing).

This is a pretty good microcosm of why I got out of the business ... there's way too much doing and not nearly enough thinking. Now, I'll grant that the decline may have really accelerated because of the impact of program trading, but that's not all of it. Institutions will program in stops at, say, the 200-day moving average, and then you can get just a cascade of selling as all of those stops trigger and force sell orders.


But it's pretty clear that people are really jittery and easily spooked these days. It seems like traders watched the news, saw unrest in Athens, and decided to de-risk their holdings. As the markets dropped, rates moved fast (as did gold, though to a lesser extent) and things snowballed.

At this point, nobody wants any risk. It wouldn't shock me to see the market close weak (despite this intraday rebound), as I doubt nervous traders want to hold equities overnight. So when you have panicky people, you get panic selling.

Is this is a great buying opportunity? I don't think so.

You and I can't buy nimbly enough to really profit off of these large intraday moves. So while I see a lot of volatility and nervousness in the near term, I think it is very difficult to play that effectively. The best advice is probably old advice - buy good stocks at prices that give you a wide margin of safety. And, to be very frank, it may just be time to step away for a bit and let things settle down.

This is *not* the end of the recovery, *not* the end of the euro, and *not* the end of the world. But what good does that do you when hyperactive traders all scream "sell" at once?

Australia Proves Taxing To Miners

The latest article on Investopedia:
http://stocks.investopedia.com/stock-analysis/2010/Australia-Proves-Taxing-To-Miners-RTP-BTU-FSUMY-ABX-NEM-FCX-VALE0506.aspx

I'll be very curious to see how debate in Australia shapes this issue. Mining is a major source of income for the country and Australia derives huge benefit from being a modern and mineral-rich nation relatively close to China. Here's hoping they don't strangle the golden goose. 

One of the biggest risks that go along with investing in mining stocks is the risk that sovereign governments will change the rules midstream. More than a few mining projects in Africa and South America have been canceled or curtailed by governments suddenly changing the rules, typically by tearing up contracts demanding a larger slice of the pie. Historically, Australia has been seen as a very mining-friendly country, but a recent proposal to change tax rules in that country has sent some major ripples through the sector.


The TaxAs part of a comprehensive tax policy review, the Australian government has proposed a new "resource super profit tax" of 40% that would be levied on companies with on-shore mining assets in Australia. In short, this tax would increase the effective corporate tax rate for mining in Australia to about 57%. Another way to look at it is that basically makes the government of Australia a 40% partner in all resource projects starting in the summer of 2012. 
 
For the full article, please go to: http://stocks.investopedia.com/stock-analysis/2010/Australia-Proves-Taxing-To-Miners-RTP-BTU-FSUMY-ABX-NEM-FCX-VALE0506.aspx 

Shopping Time In Medical Technology?

The following has been posted on Investopedia:
http://stocks.investopedia.com/stock-analysis/2010/Shopping-Time-In-Medical-Technology-MDT-VOLC-ZOLL-ABMD-THOR0506.aspx.

It is a little strange for me to see ATS Medical get a bid. We banked that company when I was just a junior analyst at Piper and the CEO/founder, Manny, was (and still is) a one-of-a-kind guy. ATSI has always been something of a sad lesson for me; sad in that it proves that the best technology/product doesn't always win and that the company with the better marketing is more likely to win. 

In any event, it's always fun to speculate on who may be next to go out in the space. I hope you enjoy the piece.  


Amidst the paper blizzard of earnings releases, a little deal in the med-tech world took place. Medical device giant Medtronic (NYSE:MDT) announced that it was buying small cardiology company ATS Medical (Nasdaq:ATSI) for about $370 million in cash and assumed debt. The deal will bring some quality heart valve technology to Medtronic and cash to long-suffering shareholders of ATS Medical.


Buy The TechnologyThe ATSI deal is a relatively minor one in the bigger scheme of things, but it does at least highlight one type of deal that could be increasingly attractive - tucking in a small company that has good technology, but has not been able to leverage it effectively. Following this mold, investors should look for companies that have acknowledged quality technology, but for whatever reasons have not been able to deliver the growth that investors want.

You can read the rest at Investopedia: http://stocks.investopedia.com/stock-analysis/2010/Shopping-Time-In-Medical-Technology-MDT-VOLC-ZOLL-ABMD-THOR0506.aspx.

Relief With Bristol-Myers Squibb

The second piece on Investopedia today - http://stocks.investopedia.com/stock-analysis/2010/Relief-With-Bristol-Myers-Squibb-BMY-PFE-SNY-AZN-MJN0506.aspx.

Although I wrote this one last week, it took a little while to get up on the site. Enjoy.


As I look at the earnings report for pharmaceutical giant Bristol-Myers Squibb (NYSE: BMY), I wonder if the rally in the stock is more of an expression of relief than excitement. Like many of its big-cap pharma brethren, there has been more than just one wall of worry to climb for BMY. 

For the rest, please go to: http://stocks.investopedia.com/stock-analysis/2010/Relief-With-Bristol-Myers-Squibb-BMY-PFE-SNY-AZN-MJN0506.aspx.

Three Growth Med-Techs Show Their Cards

The following went up this morning on Investopedia:
http://stocks.investopedia.com/stock-analysis/2010/Three-Growth-Med-Techs-Show-Their-Cards-HOLX-IRIS-VOLC-GE-CPTS-GPRO-BSX-IHI0506.aspx.

As earnings season winds down, a relatively rare trifecta occurred May 3 as three quality growth med-tech stocks reported their earnings. Hologic (Nasdaq: HOLX), IRIS International (Nasdaq: IRIS) and Volcano (Nasdaq: VOLC) all reported earnings with varying degrees of performance. 

For the full article:   http://stocks.investopedia.com/stock-analysis/2010/Three-Growth-Med-Techs-Show-Their-Cards-HOLX-IRIS-VOLC-GE-CPTS-GPRO-BSX-IHI0506.aspx.

Wednesday, May 5, 2010

Putting The Dow In Perspective

I apologize for the slowness of posting this one, but I do not get automated updates when my pieces go up on the FinancialEdge website.

Here is the article:
http://financialedge.investopedia.com/financial-edge/0510/Putting-The-Dow-In-Perspective.aspx


The Dow Jones Industrial Average (DJIA) is inescapable. No matter how middling a news outlet's coverage of business may be, it is a safe bet that the performance of the DJIA or "the Dow" will be offered up as a comment on how the market is doing.

What is often lacking, though, is a sense of context and significance. Without a bit of perspective on just what the Dow is, it's not that useful to talk about moves in the index, particularly when those moves are talked about only as points.


You can read the rest at:
http://financialedge.investopedia.com/financial-edge/0510/Putting-The-Dow-In-Perspective.aspx

My Humble Solution To The Greek Crisis

Please note - this is intended as satire, not a serious proposal, nor a political commentary.

I think I have arrived at an easy way for Greece to get itself out of this criss.

Unfortunately for Greece, its greatest days were long before the advent of the modern world and concepts like "patents", "trademarks", and "copyrights". But why should that stand in the way? There have been more than a few retroactive patents awarded in the past, and we in the United States have seen fit to grant patents for things like genetic sequences -- something that no man created, but rather just happened to be the first to find.

So, why shouldn't Greece be allowed to hold a patent on arguably its greatest invention?

Democracy.

Now, I know, Greek democracy (or rather, Athenian democracy) is very different than what we call democracy today. In fact, I daresay Athenian democracy would be barely recognizable to Americans as democracy. But let us not quibble over the details.

According to the Democracy Index, roughly 50% of the world today lives under democracy (be it perfect or imperfect). That's about 3.4 billion people, folks.

Now, when the U.S. launched military operations against Iraq, one of the stated reasons was to bestow democracy upon the Iraqi people (along with eliminating potential WMDs, getting rid of Hussein, and holding him accountable for various human rights violations and terrorist activities). So far, our operations have cost America about $704 billion dollars.

Iraq has a population of 31.2 million people. So, if we allow for one-third of the motivation being democracy, that gives us a price of $7,500 per person for democracy. And for the purposes of this exercise, we'll just treat this as a one-time payment paid by the current generation forever more.

Now, the Greeks being fair-minded people won't charge us that established "retail" price that the United States has paid. Instead, they'll grant a perpetual license for 10% of that amount - really a rather reasonable amount when you look at patent licensing agreements for novel technology and innovation.

Do the math (10% of $7,500, multiplied over 3.35B people) and you get a sum of $2.5 trillion. That is what the world, collectively, owes Greece for the right to use democracy.

So, given that the total outstanding sovereign debt of Greece is only about $400 billion, maybe the fairest approach is to call the whole thing even.

Please note - this is intended as satire, not a serious proposal, nor a political commentary.

Tuesday, May 4, 2010

No Safe Harbor?

Where do you want to invest today?

Europe? Good luck.

Europe has problems above and beyond Greece - the "green shoots" of recovery there were always scrawnier than over here, and the decision by the ECB to continue to accept Greek bonds as loan collateral means that institution's credibility is, at best, "stretched". With the possibility of banks in France, Germany, and Spain (and perhaps the UK, Italy, and the Netherlands to a lesser extent) are going to be severely hamstrung by troubles in Greece and Spain, growth in Europe could get pretty difficult. As we've learned over here, it's tough for the economy to be healthy if the bank sector is gangrenous.

The U.S.? Maybe.

I think the U.S. economy is in okay shape for now, but I'm one of the weirdos more worried about *deflation* than inflation (yes, I know public debt is onerous, I know government spending is out of control ... but I majored in Japanese back in college, and I've seen how this scenario can go). The market got over-heated and over-optimistic, but I think we at least have a credible hope to grow. For the next 12-18 months, we should be okay. The 3-year, 5-year, and 10-year horizons are scarier, though.

Emerging markets? Nope.

Brazil is raising rates. India is raising rates. China is trying to deflate a property bubble without strangling the economy. So, the three most interesting emerging markets are all trying to tap the brakes on their economies. Sometimes that works out, but more often than not that "tapping" on the brakes ends up sending the stock market temporarily into the windshield. So, now is a GREAT time to find Brazilian, Indian, and Chinese stock ideas, but I wouldn't be aggressively buying into the headwind of these governments trying to cool things down.

So, where does that leave us?
Gold? Not for me, thanks. Other commodities? Not looking so great ... some are looking strong on a short-term trade (coffee, corn, maybe cattle), but it's hard to feel great about copper sliding off (as that's often a precursor of economic conditions on a more global scale).

Bonds? Probably not, especially with the ratings agencies looking stupid (again), and rates seemingly on the rise.

It looks like we're in for one of those unpleasant periods where the predominant investment decisions are how to minimize the damage, as opposed to how to maximize the gains. But this too shall pass.

In the meantime, maybe I need to brush up on some more Turkish and Nordic stocks...

Oh Wait, Things *Aren't* Alright

So, the market sold off significantly today, allegedly due to fears that the aid package wouldn't help Greece. Really? So, yesterday "the Street" thought things would all work out just fine, but then over Cheerios this morning they all realized "oh wait ... we're all doomed".

I actually don't blame the financial media so much for this. They have a job to do, and their foremost job is to provide answers (or something that looks like answers) for the ever-present question "Why did the market go up/down today?" Nobody ever seems to need to explain a flat market ... though I feel like those are the days when we hear about "battles" between bulls and bears over the latest worries and wild hopes.

Look, Greece is bad and it's going to get worse. The "aid" package isn't going to help and will probably do little more than roil the markets and prop up some European banks long enough for them to move that Greek debt off their balance sheets in a way that doesn't totally devastate their earnings and capital ratios in the short-term. Longer term, there's just no realistic chance that this package spares Greece from default.

And that's okay. Default, like bankruptcy, should be the logical consequence of a series of bad mistakes. It's the ultimate expression of "okay, we eff'ed up ... now we need to start over". What is almost always worse, though, is what people, companies, and nations will do to stave off that bankruptcy. When people are desperate, they get dangerous. Suddenly, stupid risks and ridiculous plans seem reasonable, because the ultimate consequence (bankruptcy/default) looks the same to them. So, they flounder around and make a mess of things for everybody else because they see their downside as being limited to that worst case scenario.

As I said before, I'm not *that* worried about Greece. I'm getting hosed on my Societe Generale stock, but then I have been for a while now anyway. And I still hold that stock because I believe the company will ultimately recover and deliver value in excess of its current price. But will Greece crush us? No.

Now, if Greece, Spain, and Portugal go down, we have a bigger risk. But that's another post for another day.

In the meantime, the stock market was overbought anyway, so we have a market in search of an excuse to go down. The Greek problem is a good enough excuse for now, but even if that problem magically went away, another one would suffice.

Keep holding good stocks and hope for the best. It's dangerous to be blindly optimistic, but there's not a lot of profit in pessimism either.

(Disclosure - I own Societe Generale stock. God help me.)

Monday, May 3, 2010

Learn From Apache's Success

Here is a second piece this morning:
http://stocks.investopedia.com/stock-analysis/2010/Learn-From-Apaches-Success-APA-DVN-SU-UPL-XOM0503.aspx

Mid-major energy company Apache (NYSE:APA) is a curious case of collective amnesia in the professional investment world. Even though Apache has more than proven itself as among the best of the best, it seems as though the company is often questioned, doubted and discounted by analysts and investors.

I mean, if you look at stock performance over the last 15 years, Apache is well ahead of rivals like Anadarko (NYSE:APC), Devon (NYSE:DVN) and Canadian Natural (NYSE:CNQ), and trails only Suncor (NYSE:SU) and EOG (NYSE:EOG) among those in its "weight class". Maybe you would think that that sort of record would earn management the benefit of the doubt.

For the rest of the story:

http://stocks.investopedia.com/stock-analysis/2010/Learn-From-Apaches-Success-APA-DVN-SU-UPL-XOM0503.aspx

Becton Dickinson More Interesting Than You Think

Here's today's first piece on Investopedia. This was a stock (BDX) that I really wanted to cover when I was a sell-side analyst this last time around. Oh well ... water under the bridge.

http://stocks.investopedia.com/stock-analysis/2010/Becton-Dickinson-More-Interesting-Than-You-Think-BDX-CPHD-GPRO-LMNX-ABT-MDT-BAX-RHHBY-QGEN0503.aspx

For many years, Becton Dickinson (NYSE:BDX) has been summarily dismissed by a lot of portfolio managers as "too boring". Well, their loss. Although the stock of this diversified health care and biosciences company could not match the pace of health care all-star Medtronic (NYSE:MDT), it stacks up quite well against the likes of Abbott Labs (NYSE:ABT), Baxter (NYSE:BAX) and many other more "exciting" names. Proof, perhaps, that the steak is more satisfying than the sizzle.

A Quiet QuarterThe first quarter of 2010 was pretty much medium, with little to get excited about in either direction. Revenue growth of about 7% was in line with expectations, while the earnings per share (ex-items) were four cents ahead of the average estimate.

To read the full article, please click:
  http://stocks.investopedia.com/stock-analysis/2010/Becton-Dickinson-More-Interesting-Than-You-Think-BDX-CPHD-GPRO-LMNX-ABT-MDT-BAX-RHHBY-QGEN0503.aspx

Buy The Spill?

It's hard not to read the coverage of the oil spill in the Gulf and not start wondering whether some selective vulture capitalism could pay off here.

Everyone involved - BP (BP), Anadarko (APC), Transocean (RIG), Halliburton (HAL), and Cameron (CAM) - has taken a pummeling from the accident. It's difficult to imagine, though, that the damage is ultimately going to be as bad as the declines in the market caps all suggest.

RIG and CAM, in particular, are the names I'm looking at right now. BP is a fine producer and the decline in the stock in the wake of the blowout and rig sinking has certainly put the stock at a point where I think long-term investors will come out nicely. But BP just isn't the type of stock I normally play.

The real question here is a two-parter. First, what will the final sum be for the cleanup costs, legal fees, and settlements? This is a big spill and it was going to be expensive in its own right to clean up. Now with lawyers descending on the Gulf coast like locusts on a corn field, the odds that all involved will be in court for years have to be close to 100%.

The second part is how the expenses get apportioned between the players.

BP has publicly stated that it wasn't their people on the rig or operating the drilling. That's true ... but also irrelevant. Most drilling contracts specifically provide that the leaseholders (BP and Anadarko) are responsible for any accidents unless those accidents can be shown to be the result of "gross negligence" on the part of the driller. So, RIG is going to be on the hook for the rig itself and some related contamination expenses (diesel, etc.). On top of that, the rig was insured for about $560M, and the company carries $950M in third-party liability coverage.

Cameron was the company that made the BOP (blowout preventer), and that piece of equipment is going to get a lot of attention. Generally speaking, a BOP is supposed to prevent exactly what happened on the Deepwater Horizon, but for whatever reason it didn't. I've seen some sources indicate that the BOP was beyond its guaranteed/warrantied life, and it is at least possible that the device wasn't properly tested and maintained. In any case, CAM has a $500M liability policy to deal with cases like this. The bigger risk, though, is that if the BOP is deemed at fault (and badly made), CAM could lose a lot of share to NOV and other rivals.

Last and not least, I wonder about Halliburton. HAL was doing the cementing just prior to the blowout. Did something about that procedure trigger the explosion? In any case, HAL usually has contracts in place that indemnify them or at least limit the liability in cases like this.

All in all, it's a big mess and it's going to take months (if not years) to fully lay out the blame. In the meantime, BP is a pretty cheap stock at these levels. I'd actually prefer Apache (APA) myself, though, as it has taken a few hits along the process of this accident. I have to say I'm very intrigued by Transocean and Cameron at this levels; I've liked both stocks for a long time, but have held off because of valuations. It seems extremely unlikely that either RIG or CAM is going to have a big bill to pay as a result of this accident, and so long as neither company's products or actions are targeted as being the direct cause, the stocks should recover pretty nicely in the long run.

Friday, April 30, 2010

GlaxoSmithKline On Simmer

The last of the run for today (I think...):

http://stocks.investopedia.com/stock-analysis/2010/GlaxoSmithKline-On-Simmer-GSK-LLY-PFE-ABT-NVS0430.aspx

Why Stocks Aren't That Scary

This is my second article for Investopedia's (relatively) new FinancialEdge website:

http://financialedge.investopedia.com/financial-edge/0410/Why-Stocks-Arent-That-Scary.aspx

Reading the news these days, it almost seems like there is something a little wrong with you if you are not afraid of the stock market. We have seen two major stock market declines in less than 10 years. On top of all that is the ever-present fear of losing money.

Still, potential investors should think a little more about the real risks in the stock market. Stocks are not actually that scary, and if people keep a few points in mind, they can successfully navigate the real hazards and be at ease with investing in stocks. (If the unpleasant emotions in When Fear And Greed Take Over are allowed to influence your decision-making, they may cost you dearly.)

For the rest:
http://financialedge.investopedia.com/financial-edge/0410/Why-Stocks-Arent-That-Scary.aspx

Can Boston Scientific Ever Get It Right?

And so continues my long love affair with not liking Boston Scientific (BSX).

http://stocks.investopedia.com/stock-analysis/2010/Can-Boston-Scientific-Ever-Get-It-Right-BSX-STJ-MDT-ABT-VOLC0430.aspx

It is only fair to state that from the beginning that I have been a long-term skeptic and critic of Boston Scientific (NYSE:BSX), going back to the late 1990's when I covered the stock as a junior research analyst. Ever since, my skepticism has been rewarded as the company has made missteps and blunders too numerous to recount here. 

With a relatively new CEO at the helm and earnings fresh on the tape, it's worthwhile to take another look at this well-known name to see if anything has changed for the better.  

For the remainder of the article: 
  http://stocks.investopedia.com/stock-analysis/2010/Can-Boston-Scientific-Ever-Get-It-Right-BSX-STJ-MDT-ABT-VOLC0430.aspx

Plum Creek Gets Pruned

I wrote the following on Plum Creek (PCL), one of my favorite REITs and a stock I wish I had just held on to instead of sold a long time ago...
http://stocks.investopedia.com/stock-analysis/2010/Plum-Creek-Gets-Pruned-PCL-WY-RYN-IP-NP0430.aspx

Memo to Plum Creek Timber (NYSE:PCL) management - in the future, try not to post earnings on the same day that western Europe appears to be melting down into the financial Stone Age. 

That would be the most logical explanation to this writer, as to why the stock is down nearly 8% (as of Tuesday's close), on earnings that were at least acceptable. Still, whenever the stock of a high-quality company goes down more than it should in the absence of truly bad news, I get a little interested.  

For the rest, click on through: 
http://stocks.investopedia.com/stock-analysis/2010/Plum-Creek-Gets-Pruned-PCL-WY-RYN-IP-NP0430.aspx

WellPoint Still On Point

There will be several articles by me going up on Investopedia today (and maybe Monday). Here's the latest.

http://stocks.investopedia.com/stock-analysis/2010/WellPoint-Still-On-Point--WLP-UNH-SNY-GSK-QDEL0430.aspx

The health insurance industry has seen more than its usual share of turbulence over the past year, what with the healthcare reform debate and seemingly mandatory attacks on the health insurance industry. Through all of that, WellPoint (NYSE: WLP) has continued to run its business exceptionally well. 

Results That Get Better As You Go AlongAdmittedly, top line growth is not a preeminent reason to own WellPoint shares. For the first quarter, the company saw revenue drop a fraction of a percent, while operating revenue was down about 3%. The economy is primarily responsible for this; with rising unemployment, the company saw premium revenue drop about 2% on a similar decrease in membership. (For more, see Intro To Insurance: Health Insurance.)


The rest can be read at Investopedia: 


http://stocks.investopedia.com/stock-analysis/2010/WellPoint-Still-On-Point--WLP-UNH-SNY-GSK-QDEL0430.aspx
 

Silicon Labs - Quality Doesn't Come Cheap

The following went up on Investopedia this morning.
Enjoy!
http://stocks.investopedia.com/stock-analysis/2010/Silicon-Labs---Quality-Doesnt-Come-Cheap-SLAB-CSCO-AAPL-ADI-BRCM0430.aspx

The semiconductor business is not for the faint of heart. Lucky for Silicon Labs (Nasdaq: SLAB) shareholders, then, that they have a rather bold and skilled management team. Remember, this is a company that decided about three years ago to sell a profitable wireless business that was about one-third of the company's revenue because management foresaw increasing competition and decreasing profitability. Since that gutsy move, the company has almost completely replaced that revenue despite the recession. 

A Very Strong Quarter In The BooksSilicon Labs reported earnings April 28 that should leave its shareholders satisfied. Revenue rose 51%, while gross margins jumped almost 6%. With significantly higher gross profits, the company was better able to leverage its overhead more effectively even while reporting higher R&D and SG&A expenses. Operating income, then, was significantly higher than in the year-ago period, and the company handily beat estimates.

The rest at: http://stocks.investopedia.com/stock-analysis/2010/Silicon-Labs---Quality-Doesnt-Come-Cheap-SLAB-CSCO-AAPL-ADI-BRCM0430.aspx

Thursday, April 29, 2010

Canadian National Needs To Do More

Here is an analysis of Canadian National (CNI) that I wrote for Investopedia.

I wish I had had the space to go into some of the complaints that have been lodged against CNI by its customers, and the possibility of regulatory involvement in Canada as a result. I don't think it really moves the needle with the company or stock, but it gives a different perspective on how the company conducts itself.


http://stocks.investopedia.com/stock-analysis/2010/Canadian-National-Needs-To-Do-More-CNI-UNP-CSX-GWR-KSU0429.aspx

It is an odd quirk of Wall Street that the best operators in an industry do not always get the most respect from analysts and buy-side fund managers. I think the reasoning is basically that the underperformers have the most room for improvement, and this hoped-for improvement constitutes a "catalyst" in the lexicon of the Street.  

So, in an earnings season where rival rail operators Union Pacific (NYSE: UNP) and CSX (NYSE: CSX) have already reported strong earnings, an "all right" performance from Canadian National (NYSE: CNI) gets a cooler reception. 

For the rest, please click on to:
http://stocks.investopedia.com/stock-analysis/2010/Canadian-National-Needs-To-Do-More-CNI-UNP-CSX-GWR-KSU0429.aspx

Wednesday, April 28, 2010

Can BBVA Be B-B-Believed?

Amidst all the talk of Europe going back to a financial Stone Age, we got to see the earnings from Spain's second largest bank, Banco Bilbao Vizcaya Argentaria (BBVA). In a way, it was something of an anticlimax - no howls of pain, no eye-popping losses, no dire projections or grim predictions of failure. It was an okay report ... maybe almost too okay?

Gross loans were down just slightly from last year, and up a little on a sequential basis. Spain's unemployment is 19%, Portugal's is about 9% (though I've seen a wide range on this stat), and Mexico's is officially about 5 or 6% (but common assumption is that the real rate is much higher). So who, exactly is BBVA lending to? I mean, I realize loans don't disappear just because the economy is bad, but it's just the first oddity that hit me.

Net interest income was up a bit from last year, and down a little on a sequential basis. Deposits were likewise mixed - up a little on a yoy basis, down a little sequentially. Okay, no big deal there. 

Here's where things get really squirrely for me. The non-performing assets ratio was flat from December, at 4.3%, and up from last year's 2.8%. Impairments were up 17% from last year to 1.1B, but down a fair bit from December. Provisioning was up about 8% sequentially (to 9.3B) and up 73% from last year's level. Surprisingly, the company has also been showing really strong recoveries as part of its non-performing assets -- recoveries of 2.4B were booked this quarter, and that was up 20% sequentially and nearly double the year-ago level.

On a net basis, then, the company added 874M euros to NPA, the lowest rate of increase in quite a while; half of December's increase, and a third of last year's. The coverage ratio has gone from 76% in March of 2009 to 59% now.

Now let's just think about this for a moment. With everything we've been seeing in Spain, Portugal, Mexico, and so on, do you really think it makes sense that coverage ratios are decreasing and net provisioning additions should be declining?

BBVA's actions seem to be suggesting that the worst is over ... but the general thought seems to be that trouble has only begun in Spain. What makes this even worse is that Spanish banks used to have a reputation for playing a little fast and loose with numbers - being slow to classify loans as non-performing, extending new loans to bad debtors to allow them to continue making payments on the prior loans, etc, etc.

Now, I happen to like BBVA to a point. I generally like the markets that the company is in, and I think there is good long-term growth potential here. But something about this earnings release just doesn't sit well with me. I hope I'm misinterpreting things or making mountains out of molehills. If I'm right, though, and my suspicions have merit, then BBVA management may be fiddling while their credit burns.

If you have a lot of confidence that Spain and Portugal will somehow walk through the minefield safely, and a faith that BBVA's management is taking a conservative approach to their credit, then this may be a great opportunity to buy while everyone else is panicking.

I, however, don't have that kind of confidence, nor that strong of a stomach. So I'll sit tight for now. I wish BBVA the best and will keep them on the watchlist, but I want to see at least a couple more quarters before I pony up my own cash for these shares.

The Easy Way To An Organized Budget

This article is a little different than my normal work.
Investopedia has developed a site that's more focused on personal finance topics, and I'm writing for this side of the business as well.

So, this won't be the usual buy-sell-hold, but I hope that it's useful all the same.

http://financialedge.investopedia.com/financial-edge/0410/Budget-Smarter-With-Earmarks.aspx

Imagine waking up one day and seeing the sky through a hole in your roof. Or think about what you would do if some knucklehead wrecks your car on the way home from work. Can you write a check without worrying about going into debt or seriously digging into your savings?

We all know that we are supposed to save money for a variety of future needs like emergencies, retirement or big-ticket items. What is not mentioned is how to go about doing this. Creating a budget spreadsheet and earmarking your savings to specific categories is an easy way to make sure you are meeting your savings needs and goals.

The rest at: http://financialedge.investopedia.com/financial-edge/0410/Budget-Smarter-With-Earmarks.aspx

Cummins Comes On Strong

Another piece recently published on Investopedia.
I definitely have a soft spot for industrial tech companies like Cummins ...

(please note: something a little goofy happened to the first paragraph in the editing process. We're working on it...)

http://stocks.investopedia.com/stock-analysis/2010/Cummins-Comes-On-Strong-CMI-TTM-DCI-CAT-ARM0428.aspx

All Clear In Energy Services?

Here is the latest article of mine on Investopedia. I should note that there was a bit of a holdup in the editing process, so this may read as slightly dated. The basic themes in the piece are still very much relevant and timely, though, so I hope you find it interesting.

http://stocks.investopedia.com/stock-analysis/2010/All-Clear-In-Energy-Services-SLB-DO-ESV-HAL-WFT0428.aspx

The last few quarters have not been the easiest for energy services sector, as troubles in Mexico, lower activity in the Gulf, weather difficulties, and project delays have all led to lower demand and lower prices. Still, it was not as though the sector closed up shop, as many U.S. natural gas shale play are economical below the $4 natural gas price level.

On a more positive note, it looks like the operating conditions may be about to turn. The earnings and commentary we have seen from the past week was supportive, and should give fundamentally-inclined investors a bit more evidence that the turn in the business is real. 

For the rest of the article: 
  http://stocks.investopedia.com/stock-analysis/2010/All-Clear-In-Energy-Services-SLB-DO-ESV-HAL-WFT0428.aspx

Tuesday, April 27, 2010

From Sons of Athens ... to Sons of Anarchy




Thanks Greece.

Virtually every financial system is built upon a certain level of trust and good faith amongst its members, and Greece seems to have taken up the role of "turd in the punchbowl". Greece basically lied their way into the European Union, gorged on cheap debt, wasted it on unproductive assets, and then turned around and held the financial system hostage with a version of "bail us out … or else!".

Of course, anybody wasting their time bashing on the Greeks is overlooking events a little closer to home. Let's see … lying to get favorable loans, using those loans foolishly, and then whining, wheedling, and begging for a bailout. Where have we seen that before?

Oh yeah, that's right. We did that too.

Now we have the S&P lowering Greek debt to "junk" (way to be on the stick ahead of time, guys … oh wait, we've seen that before too!), Greek 2-year notes yielding about 19%, and a lot of people nervously watching Portugal, Spain, and Ireland for signs of weakness.

Think about that for a moment … Greek 2-year notes are yielding almost 19%. That's like credit card rates. On second that, maybe I shouldn't have said that … Capital One (COF) may soon be seeing a flood of applications from Athens at this rate.

The scary part, though, is how long this could last. Latvia went into crisis a little while ago and even massive cuts to government wages, pensions, and spending (and other austerity measures) didn't help much. Greece, then, could be looking at quite a few years of high taxes, a sharply contracted public sector, malaise, and discontent. Not too many countries have the capability to withstand that, and there could be unrest as a result (as seen a few years back in Argentina).

It's almost a given that the "market" won't be much help here, and the rescue package will have to come out fully-funded by other European countries. On top of that, you're probably looking at wage cuts of 20% or higher as part of the package, and I don't think many Greek civil servants will be happy about that. Worse still, after 12 or 18 months of that, it may still not be enough and Greece may opt to default/restructure that debt and send more ripples of chaos through the market. Simply put, we're talking here about a program that would take four or five years … and that's assuming that Portugal and Spain don't fall over and make it even worse.

In the meantime, a lot of banks have gotten smacked already. Several German and French banks have (or had) major exposure to Greece, with names like Commerzbank, Credit Agricole, Societe Generale and BNP Paribas among them. The damage there is probably already done, but I'd be very cautious around any banks heavily exposed to Spain … or frankly almost any European country at this point.  After all, plenty of British banks have loans on the books for vacation homes in Spain, so you can never just assume a bank in Country X is safe.

Sooner or later, this storm will pass. The U.S. economic recovery isn't heavily predicated on Europe at this point, though chaos in the credit market can quickly become a global issue. But that isn't to say that the fallout won't cause some chaos and hairy days. Expect talk to begin about creating a mechanism to boot out European Union countries that can't get their stuff together, and should the Euro actually collapse … well, that's probably a really good day to own gold (and probably dollars as well, because as messed up as we are, we're not that bad).

Here's hoping the sons of Athens figure a way out of this mess before it gets too much worse.

(Disclosure - I own shares of Societe Generale)








Monday, April 26, 2010

Viva la FEMSA!

Another one of my companies announced earnings today, this time it was Mexican consumer conglomerate FEMSA (FMX) reporting after the close. Although the results weren't a blowout, they were good enough.

Revenue was up a bit more than 6%, operating income was up almost 10%, and net income was up more than 150% as a lot of "other expenses" weren't repeated. Perhaps just as important for the short-term, the results were basically in line with the analyst estimates.

The company's Coca-Cola business saw revenue up about 5% and operating income up more than 6%, while the beer business saw operating income up almost 13%. Last and certainly not least, the company's Oxxo business posted nearly 29% operating income growth on same-store sales growth of 3%.

I'll be the first to admit that none of those numbers are great for a "growth" stock, but there were at least a few mitigating factors. Mexico's economy is in a rough patch too, particularly in the border regions, and that did no favors for the Coca-Cola and Oxxo businesses. Longer term, though, I still think there's a lot of leverage and potential left in these businesses -- particularly in the Oxxo business, which the company has only now just started to expand outside of Mexico.

Conglomerates pretty much always trade at a discount, and FEMSA is no exception (even if it's not as much of a conglomerate as, say, Nestle (NSRGY) or Pepsi (PEP)). Even with that handicap in place, though, there's an arbitrage opportunity with the Coca-Cola business (it's relatively cheaper to buy FEMSA than Coca Cola FEMSA (KOF)), the Heineken shares that the company is getting in exchange for the beer business, and growth opportunities still ahead with the Oxxo business.

All in all, I'm still quite happy to own FEMSA shares here. Yeah, it's not as exciting as some China stock, but you should be able to get another 20-25% out of this stock before it's trading at parity with its closest comps. That's good for a "Buy" for me.

WRB and ACGL - Two Great Insurance Companies

WRIt was a happy coincidence that two of my favorite insurance companies reported today. W.R. Berkley (WRB) is an exceptionally well-run (if somewhat "quirky") specialty insurance company, while Arch Capital (ACGL) is a player in the reinsurance segment of the market.

I'm not at all surprised to see that WRB posted slightly lower-than-expected revenue, but better-than-expected earnings. WRB is an efficient operator and a very disciplined underwriter -- if the prices aren't up to their standards, the company walks away. When you hear Berkshire Hathaway's (BRK.A) Warren Buffett talk about how most insurance companies lose money on their underwriting, that's why -- they feel like they have to "stay in the game" no matter what the cost. WRB doesn't play that game; if they don't like the terms, they take their money and go home.

So, as a result, gross premiums were down about 2% and net premiums were down about 4%. Operating income was down about 4% as well, though the bottom line result was still about $0.10 better than the average analyst guess. Along the way, book value rose almost 4% from December, and the ROE came in at 13.2%.

Admittedly those don't sound like numbers to do handstands over, but they should be kept in the context of a pretty soft insurance market - rates aren't very good, a lot of companies still have turbulence in their investment portfolios, and analysts aren't too keen on the sector as whole. But that's the point where I get interested in buying -- and I think WRB is an excellent insurance stock to buy in a soft market.

Similar to WRB, Arch Capital posted a beat on earnings and a miss on revenue and it was largely for the same reasons I talked about before; namely, that Arch won't write business that doesn't meet it standards. Right now, that's a problem ... but soft markets have a way of turning into hard markets and Arch Capital will reap the benefits when that turn comes.

Here too, the details don't look spectacular -- gross premiums were down 7%, operating income was down from last year, and the posted ROE of just under 10% isn't all that remarkable. Once again, though, the bottom-line results were better than conservative estimates and this is a company where there can be a lot of operating leverage when pricing firms up.

Arch might be a stock where you want to wait a bit before buying ... namely, until the hurricane season is underway. Major catastrophes like hurricanes are the risk factor for Arch, though experience and history suggests that the company has spread its risks around in such a way that a single major storm (or even several) wouldn't represent a devastating economic loss to the company. Still, by the time the "all clear" has sounded, it may be too late. So investors willing to absorb a little risk might just want to look at these shares now and trust that management's underwriting standards will continue to make this a top idea in the insurance space.

Saturday, April 24, 2010

BB&T - Patience Will Pay Off

I have been pretty outspoken in my appreciation of BB&T (BBT) management and the stock. During the credit crisis, BBT held up a fair bit better than most banking stocks, even though there was a steady drumbeat from analysts worrying about the company's commercial loan portfolio. With this week's earnings, it looks like things are slowly getting better at BBT, though the process of full recovery may take a little longer here than at other banks.

Results for the first quarter were alright. The company beat by $0.04 on an as-reported basis ($0.27 versus $0.23), though reported earnings were about a penny higher than the real earnings. Net charge-offs were 1.84% and the rate of increase has slowed down. For the full year, the company said it expects NCOs to average about 1.8%.

Provisions for the quarter were $575M, about 2.65% (versus 2.55% in December), while gross charge-offs were $509M. Deposits were up about 5% excluding the Colonial deal, while loans were down 4.3%. Some of this loan decline was seasonal, but management did say they were pulling back on deposit growth because they didn't see the loan demand to justify it. Non-interest income was down because of lower gains from securities and lower mortgage banking.

The real debate about BBT is going to center around the credit situation. Past due loans seem to have flattened, and that could be a sign that things have stabilized. I expect some analysts and buy-siders to be worried about the company's big jump in troubled debt restructurings (TDR). These climbed 60% sequentially to $1.7B. The bear case is going to be that the company is being too slow in recognizing loan losses and this is going to slow down the return to "normal" by at least a few quarters.

The company would counter by saying that they applied a separate underwriting process to these TDRs and they didn't restructure any loans that they didn't think would be repaid. So, in short, BBT is relying upon their underwriting standards. Given that the company has done quite well relative to its peers in terms of loan losses and underwriting, I'd be inclined to go along with management on this one. Maybe the TDRs do push out "normal" by a quarter or two, but you haven't made much money over time by betting against BBT management.

Much as I like BBT, and am happy to own the shares, I'm not sure that I'd be pounding the table right now. By my calculations, the stock is about 5 - 10% undervalued, and that's not much of a margin of safety. USBancorp (USB) and Wells Fargo (WFC) both seem relatively cheaper, as does JPMorgan (JPM), PNC (PNC) and a host of smaller, riskier banks. By the same token, BBT rarely ever gets cheap and you could do a lot worse than buy-and-hold this one.

(Disclosure - I own BBT and JPMorgan shares)

Thursday, April 22, 2010

Putting On My Tin Foil Hat

Okay, this is a wild conspiracy, but just hear me out.

The administration wanted to fight against rising medical device and drug prices (and get health care reform passed over industry objections). Suddenly there are antitrust investigations in a couple sectors of the med-tech market (immunohematology, plasma-derived drugs) and rumors of sniffing around for more (hospitals, drug companies, ICDs). The administration has also talked about revoking the antitrust exemptions for the health care insurance industry.

The administration is going after seed companies (specifically Monsanto), is rumored to be looking very carefully at the transport sector, and has publicly warned the petroleum industry that investigations could come.

And now we have the Goldman Sachs suit. Now I don't know whether or not Goldman committed fraud, but having worked on the buy-side in fixed income during the credit crisis, I'm not the least bit surprised that there was self-dealing. I mean, it was basically accepted as fact that some of the brokers were shorting mortgage-backed securities (and related derivatives) while simultaneously creating, packaging, and selling them to investors.

This shouldn't be a big surprise to anybody; these are the same companies that cheerfully banked miserable tech companies in the late 90's, sold them to investors with glowing research reports, and made sure they didn't get caught long on their trading desks because they knew they were crap.

So, anyways, is it fair to wonder whether the Goldman suit is a blunt instrument of policy aimed at telling Wall St. "back off on opposing reform, or we'll nail you and embarrass you even further"? I mean, really, who is going to leap to the defense of those "damn greedy bankers"?

Like I said at the beginning, this is just mostly gonzo conspiratorial theorizing on my part. After all, the Bush administration was uncommonly lax when it came to antitrust investigations and enforcements (in terms of the number of cases pursued compared to past administrations). So maybe we just have aggressive new people in place, and maybe they're making up for lost time and overlooked sins.

Or ... maybe not. Maybe this is how business is going to be done for a few years -- we'll ask you to cooperate, then we'll send a shot across your bow.

Time will tell...

Disclosure - I own shares of Monsanto.

Regional Bank Round-Up

Here's a piece that went up on Investopedia today. It was written a few days ago, so it does not include the major bank earnings that were announced since then.

http://stocks.investopedia.com/stock-analysis/2010/Regional-Bank-Round-Up-USB-ZION-RF-MTB-KRE-WFC-PNC0422.aspx

It seems that banks got us into this mess, but are they finally getting themselves out? If you look at the performance of the stocks, at least as measured by the SPDR KBW Regional Banking ETF (NYSE:KRE), it is tempting to say "yes". After all, regional banks have done well so far this year relative to the S&P 500; up about 25% versus a roughly 7% gain in the broader market index.

If only it were that simple. We have all seen that the market is a measure of what people think is going to happen, and not necessarily an accurate measure of what is happening on the ground. Luckily for all us, a recent batch of big regional bank earnings does suggest that business is looking up.

The rest can be read at:
http://stocks.investopedia.com/stock-analysis/2010/Regional-Bank-Round-Up-USB-ZION-RF-MTB-KRE-WFC-PNC0422.aspx
 

Wednesday, April 21, 2010

First Cash Financial - The Real Pawn Star

Another quarter in the books for First Cash Financial Services (Nasdaq: FCFS), and another reminder to me of why I've held on to this stock for so many years.

Revenue this quarter was up 21% and income from continuing operations was up another 20%. Pawn receivables (which you can think about as something of a preview of future revenue) were up 29%, with over 46% growth in pawn receivables in Mexico. Inventory turns improved pretty significantly, and overall same-store sales were up about 14%.

Mexico has been a big part of this company's growth plans for a while, and that doesn't look to be slowing down. The company opened 14 stores this quarter, and all of those were in Mexico. In fact, about half of this company's revenue comes from Mexico. Given the relatively easier regulatory climate in Mexico, I can't see any good reason for the company to do otherwise -- there's plenty of room to expand in the U.S. (the company operates in just 8 states), but advocacy groups have aggressively targeted payday lending (a small part of FCFS's business) and have periodically gone after pawn operators as well.

Said differently, if you can get nearly 30% revenue growth from Mexico, why bother with the hassles in the U.S.?

Like most companies I own, FCFS continues to generate some pretty prodigious cash flow, and management has been building up cash. Hopefully they're not about to do another dumb deal (buying a buy-here/pay-here auto sales business a couple of years ago was a disaster), and that they'll apply the funds either to share buybacks or further expansion into new markets. Who knows, maybe it's time for them to start investigating Brazil (though there's plenty of room left to grow in Mexico).

This stock has always been relatively volatile and I'm not sure I'd rush to buy today, but I'm not looking to sell any shares and I'm quite content to sit tight as an owner.

(disclosure - I own shares of FCFS)

Tuesday, April 20, 2010

ICU Medical - The Roller Coaster Ride Continues

ICU Medical (ICUI) has always been an unusually volatile stock, mostly due to the company's reliance/relationship with Hospira (HSP). I had hoped that with ICUI's acquisition of HSP's critical care business and the company's expansion of domestic distribution, that volatility would ease up.

Silly wabbit.

ICUI missed on the top and bottom lines, and is taking a spanking in the market today. 

To some extent, this quarter was a "ghost of Hospira" situation, as the critical care business once again under-delivered the goods. Sales were softer than I had been hoping and yet the influence of these sales was still sufficient to lower the gross margin more than I had expected.

On the plus side, the company's core CLAVE business was quite strong, even as the custom tubing business was a little weak. What's more, the company saw great growth in domestic distribution and overseas sales, and Hospira was about 37% of the company's sales. On top of that, the company is apparently making great progress with its plant (under construction) in Slovakia. This plant could be a key catalyst for improving overseas growth; a very under-penetrated market for ICUI.

I still think that this year will be something of a kitchen sink for the company, as management tries to repair the badly neglected critical care business that it bought from Hospira and as the company faces various costs in opening that plant in Slovakia. Longer term, though, I think the company can get a lot of leverage out of both -- critical care is a decent market with only one real competitor (Edwards (EW)) and a little attention and focus here could reap some meaningful cash flow and growth. With the Slovakia plant on line, the company could look to several years of strong (25%+) revenue growth with even better margins and more predictability.

And hey, let's not forget that management basically maintained its guidance -- suggesting that the first half of the year may be a little worse than I'd hoped, but that the second half could be meaningfully better. 

ICUI is a stock that will drive you crazy, but I think you can buy it here and make decent money on it. It's not going to be a go-go grower like Intuitive Surgical (ISRG) or a darling like Illumina (ILMN). What it is, though, is a proven generator of ample cash flow and a management team that does not waste shareholders' time or money.

At this price, I have to admit that I'm thinking of adding it to my own PA.

Monday, April 19, 2010

The Shape of Dry Bulk Shipping

Here is today's Investopedia piece.

http://stocks.investopedia.com/stock-analysis/2010/The-Shape-Of-Dry-Bulk-Shipping-GNK-EXM-DRYS-NM-EGLE0419.aspx

Those huge panamax and capesize freighters may look peaceful as they sail slowly across the oceans, but the stocks behind them are anything but. Betas in the dry bulk space are exceptionally high, with many companies sporting betas above three. Pick the right stock at the right time, and it is easy to see how shipping built the fortunes of many a magnate. Of course, picking the wrong stocks can be like tying your money to an anchor and tossing it over the side. 

You can read the rest at:
http://stocks.investopedia.com/stock-analysis/2010/The-Shape-Of-Dry-Bulk-Shipping-GNK-EXM-DRYS-NM-EGLE0419.aspx

Friday, April 16, 2010

The Delicate Dance of the Banks

So now we have Bank of America's (BAC) earnings in hand as well. Like JPMorgan (JPM), they were better than expected, though not as strong on a relative basis. Like Morgan, BAC saw weak loan growth, good i-banking revenue, and very good trading revenue. There were also continued large reserves taken for the mortgage business.

This is a very delicate little dance we have going on here.

Trading is a fickle business and that revenue could go away fairly quickly; whether from rising interest rates, a federally-imposed restriction on proprietary trading, less volume, or what have you. The recovery in credit cards could also go away quickly if the economy takes another leg down. Last and not least, commercial lending has held up despite everybody's expectation and while that's not as large a business for the JPM/BAC size of bank (relative to the big regional banks), it could mushroom into a big problem.

What it all boils down to for me is this - the easy money in American bank stocks has been made. The economy will get better, bank earnings will improve, and bank stocks have room to go up. But whereas buying bank stocks 18, 12, or even 6 months ago was a decision where you were exploiting excessive fear in the market, that cushion is gone.

On the flip side, the insurance industry hasn't been getting all that much love, but that's a topic for another day...

(disclosure: I own JPMorgan shares)

Thursday, April 15, 2010

Small Med-Tech Names You Should Know

A quirk of timing led to me having two articles posted today on Investopedia.

Here is the second one.


http://stocks.investopedia.com/stock-analysis/2010/Small-Med-Tech-Names-You-Should-Know-ICUI-IRIS-LMNX-HSP-ILMN0415.aspx


Small Med-Tech Names You Should Know

Healthcare is a huge space, and for every Medtronic (NYSE:MDT) or Pfizer (NYSE:PFE), there are dozens of quality names that go unnoticed by the investing public. A little time and effort, though, can uncover some intriguing names that may deserve a place in investors' portfolios. Today we highlight three ideas.

http://stocks.investopedia.com/stock-analysis/2010/Small-Med-Tech-Names-You-Should-Know-ICUI-IRIS-LMNX-HSP-ILMN0415.aspx

If You Can't Beat 'Em, Buy 'Em

Here is today's piece from Investopedia.
http://stocks.investopedia.com/stock-analysis/2010/If-You-Cant-Beat-Em-Buy-Em-XOM-XTO-HAL-RIG-UPL0415.aspx

Interesting coincidence that the APA-ME deal was announced this morning as well, given the theme in this piece.

Although a couple of deals does not necessarily make a trend, investors should get ready for a wave of M&A in the energy sector. We saw the Exxon Mobil (NYSE:XOM) - XTO Energy (NYSE:XTO) deal a few months ago, the deal between Arena Resources (NYSE:ARD) and SandRidge Energy (NYSE:SD)about a week ago and now the announced transaction between Haliburton (NYSE:HAL) and Boots & Coots (AMEX:WEL).

I believe these are just the first moves in a larger trend. With the credit and equity markets a little closer to normal, rising energy prices and increasing pressures on large energy company executives to "do something," merger and acquisition activity is going to look like an increasingly attractive option to many CEOs

The rest of the story at: 
http://stocks.investopedia.com/stock-analysis/2010/If-You-Cant-Beat-Em-Buy-Em-XOM-XTO-HAL-RIG-UPL0415.aspx 

I Want To Cry ... No, Wait ... I Want To Scream

This morning I wake up a little late, look through the news ... and suddenly feel quite depressed. Apache (APA) has announced that it's buying Mariner Energy (ME) for about $26 a share in stock and cash.

Why do I care?

Because ME was sitting right at the top of my to-buy list ... Hell, I was expecting to place the order later today or early tomorrow.

If there's good news here, it's that APA is paying almost exactly what I think ME is worth. So, I'm not happy to be missing a 50% gainer, but at least I know my methodologies for valuing E&P companies isn't totally off-base (or if it is, at least APA is just as wrong as I am).



Back to the drawing board.

Wednesday, April 14, 2010

Jamie Dimon, You Magnificent Bastard

With JPMorgan reporting earnings this morning, and beating estimates, I'm a happy owner who is once again reminded of the virtues of having top-notch management at the head of the companies they own.

JPM beat bottom-line estimates by $0.10 this morning ($0.74 v. $0.64), and the details in the release were quite sound. Credit provisions were pretty sound, and Dimon was damn-near ebullient when talking about the business and it's near-term prospects. Dimon, like most bankers, is not a guy given to blowing sunshine, so for him to get excited means something to me.

I-banking was really, really strong this period. I don't have a great sense of their marketshare yet, but my sense of it is that they're definitely making some gains.

Retail banking and credit cards were both soft. Is anybody surprised? I thought it was interesting to see the provisioning in both businesses to be roughly equal, even though the banking business is quite a lot bigger. Of course, most people will save their house before they'll save their plastic, so it's not a huge shock.

The one thing I'm not thrilled about was the ROE. I mean, ROE comes down to math and I'm not shocked that this metric didn't pick up, but it's the one issue I'm worried about. As a matter of fact, I would not be surprised to see Dimon over-provisioning the company and seeing a sizable jump in that ROE in a couple year's time. In the meantime, this company is quickly starting to leave some of its would-be competitors in the dust.

I'm a happy owner here and I'll continue to be an owner. And these results should make anybody holding shares of banks like BB&T, USBancorp, Bank of America, et. al feel a lot more comfortable.

Disclosure - I own shares of BBT and JPM

Monday, April 12, 2010

Investors Could Reap Profits From Monsanto

Here's the latest article of mine on Investopedia:
http://stocks.investopedia.com/stock-analysis/2010/Investors-Could-Reap-Profits-From-Monsanto-MON-DD-SYT-POT0412.aspx

One of the classic clichés of the investment world is that "trees don't grow to the sky"; sooner or later, the mightiest of stocks stumbles. Investors who have been around a few years can no doubt recall plenty of examples ranging from Dell to Amgen, to even mighty Microsoft.

Now it is Monsanto's (NYSE:MON) turn.

How Monsanto Lost its Groove
This agribusiness giant has been a stellar performer in the stock market for most of its history, but performance stalled out in 2008 and has not come back since. With Wednesday's earning release, and a significant adjustment both to guidance and the company's operating philosophy, it seems that many of the analysts and professional investors who were not already souring on Monsanto are heading to the sidelines.

The rest can be found at: http://stocks.investopedia.com/stock-analysis/2010/Investors-Could-Reap-Profits-From-Monsanto-MON-DD-SYT-POT0412.aspx

Wednesday, April 7, 2010

And we're back...

After more than a year in sleep mode, I'm bringing this blog back to life.
Not sure what it's going to be ... maybe just a listing of articles I do for Investopedia et.al, or maybe something a little more comprehensive and involved. Time will tell...